Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy

References

• Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988–1996. Eur J Cancer 2000; 36: 1965–8
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000; 335: 1822
   Google Scholar
• Mouridsen HT, Bjerre KD, Christiansen P, Jensen M-B, Møller S. Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry. Acta Oncol 2008; 47: 525–36
   PubMed Web of Science ®Google Scholar
• Felay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–92
   PubMedGoogle Scholar
• Tejler, G, Norberg, B, Nordenskjöld B on behalf of the South East Sweden Breast Cancer Group. Survival after treatment for breast cancer in a geographically defined population. Br J Surg 2004;91:1307–12.
   PubMed Web of Science ®Google Scholar
• Svenska bröstcancergruppen. Nationella riktlinjer för behandling av bröstcancer. http://www.swebcg.roc.se/natriktlinjbrca2007.htm.
   Google Scholar
• Stål O, Hatschek T, Carstensen J, Nordenskjöld B. DNA analysis in the management of breast cancer. Diagn Oncol 1991; 1: 140–54
   Google Scholar
• Stål O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist LE, et al. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993; 9: 1717–22
   Google Scholar
• Remvikos Y, Mosseri V, Asselain B, Fourquet A, Durand JC, Pouillart P, et al. S-phase fractions of breast cancer predict overall and post-relapse survival. Eur J Cancer 1997; 4: 581–6
   Google Scholar
• Daidone MG, Silvestrini R. Progostic and predictive value of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst 2001; 30: 27–35
   Google Scholar
• Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, et al. Prognostic relevance of three histological grading methods in breast cancer. Int J Oncol 2001; 6: 1271–7
   Google Scholar
• Rosen PP, Groschen S, Saigo PE, Kinne DW, Hellman S. A long term, follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7: 355–66
   PubMed Web of Science ®Google Scholar
• Sydöstra bröstcancergruppen. Vårdprogram för bröstcancer stadium I. Onkologiskt Centrum för Sydöstra Sjukvårdsregionen, Regionsjukhuset i Linköping, 1983.
   Google Scholar
• Sydöstsvenska bröstcancergruppen. Vårdprogram för bröstcancer. Sydöstsvenska Bröstcancergruppen och Onkologiskt Centrum för Sydöstra Sjukvårdsregionen, Universitetssjukhuset i Linköping, 1992.
   Google Scholar
• Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group (SBCCG). Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543–9.
   PubMedGoogle Scholar
• Ejlertsen B, Mouridsen HT, Jensen M, Andersen J, Cold S, Edlund P, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84
   PubMed Web of Science ®Google Scholar
• Fernö M, Stål O, Baldetorp B, Hatschek T, Källström A-C, Malmström P, et al. South Sweden Breast Cancer Group and South-East Sweden Breast Cancer Group. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. Breast Cancer Res Treat 2000; 59: 69–76
   PubMedGoogle Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457–81
   Web of Science ®Google Scholar
• Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Wiley, New York 1980
   Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187–220
   Google Scholar
• Hammar M, Brynhildsen J, Dabrosin L, Frisk J, Lindgren R, Nedstrand E, et al. Hormonal replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 1996; 25: 193–9
   PubMed Web of Science ®Google Scholar
• Brynhildsen J, Björs E, Skarsgård C, Hammar M. Is hormone replacement therapy a risk factor for low back pain among postmenopausal women?. SPINE 1998; 7: 809–13
   Google Scholar
• Ekblad S, Bergendahl A, Enler P, Ledin T, Möllen C, Hammar M. Disturbances in postural balance are common in postmenopausal women with vasomotor symptoms. Climacteric 2000; 3: 192–8
   PubMedGoogle Scholar
• Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 6: 1387–92
   Google Scholar
• Fernö M, Baldetorp B, Bendahl PO, Borg A, Ewers SB, Olsson H, et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen – especially for progesterone receptor positive tumours with a high proliferation. Breast Cancer Res Treat 1995; 36: 23–34
   PubMedGoogle Scholar
• Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. Systemic treatments for women with breast cancer: Outcome with relation to screening for the disease. Ann Oncol 2003; 14: 1212–4
   PubMed Web of Science ®Google Scholar
• Jatoi I, Miller AB. Why is breast-cancer mortality declining?. Lancet Oncol 2003; 4: 251–4
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant adjuvant chemotherapy. NEJM 1997; 337: 949–55
   PubMed Web of Science ®Google Scholar
• Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Lancet 1999; 353: 1641–8
   PubMed Web of Science ®Google Scholar
• Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, et al. Reduced incidence of distant metastastis and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007; 196: 342e1–9
   Google Scholar
• Desmedt C, Sotiriou C. Proliferation: The most prominent predictor of clinical outcome in breast cancer. Cell Cycle 2006; 5: 2198–202
   PubMed Web of Science ®Google Scholar
• Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 4059–66
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262–72
   PubMed Web of Science ®Google Scholar